Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003485643 | SCV004238422 | likely pathogenic | Leber congenital amaurosis 4 | 2023-11-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003485643 | SCV004296479 | pathogenic | Leber congenital amaurosis 4 | 2023-11-27 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with histidine, which is basic and polar, at codon 155 of the AIPL1 protein (p.Gln155His). RNA analysis indicates that this missense change induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs758001091, gnomAD 0.01%). This missense change has been observed in individual(s) with AIPL1-related conditions (PMID: 30718709). It has also been observed to segregate with disease in related individuals. This variant is also known as p.(H93_Q155del). ClinVar contains an entry for this variant (Variation ID: 635994). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this missense change results in skipping of exon 3, but is expected to preserve the integrity of the reading-frame (PMID: 26650897). For these reasons, this variant has been classified as Pathogenic. |
Ophthalmic Genetics Group, |
RCV004794454 | SCV005415449 | likely pathogenic | Retinal dystrophy | 2024-05-27 | criteria provided, single submitter | research | |
Department of Clinical Genetics, |
RCV000787530 | SCV000926498 | uncertain significance | Leber congenital amaurosis | 2018-04-01 | no assertion criteria provided | research |